Tracers / [90Y]Y-anti-CD66

[90Y]Y-anti-CD66

Also written as [Y-90]Y-Anti-CD66; [Y-90]anti-CD66

Radionuclide: Y-90 t½ 3843.6 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 1

Dosimetry and biodistribution studies Leukemia (acute and chronic)

What it is

Compound class: DTPA-conjugated anti-CD66 monoclonal antibody (radioimmunoconjugate)
Target / mechanism: CD66b-specific monoclonal antibody targeting bone marrow myeloid cells PMID 37509321
Clinical application: Radioimmunotherapy for bone marrow targeting as part of conditioning before allogeneic hematopoietic cell transplantation in acute myeloid leukemia, myelodysplastic syndrome, or acute lymphoblastic leukemia PMID 37509321
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	custom manifold	SPE	50-57% no	96-99% (mean 98% ± 1%)	DTPA-Bn-CHX-A″-anti-CD66 Curium/Cisbio International, Scintimun	37509321 2023 Cancers (Basel) For radiolabeling, 8600 MBq of 90Y was obtained from Eckert & Ziegler (Berlin, Germany) in a 0.04 molar HCl solution. — resulting in a total amount of 3991 ± 973 MBq (50–57% radiochemical yield, not decay corrected)

Need this precursor?We can point you to suppliers for [90Y]Y-anti-CD66, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37509321: '[90Y]Y-DTPA-Bn-CHX-A″-anti-CD66-mAb'. | Stage 28: added indication(s) onc-leukemia from consolidated missing-rubric review.